BR112017024719A2 - compostos de hidroxil purina e seu uso - Google Patents
compostos de hidroxil purina e seu usoInfo
- Publication number
- BR112017024719A2 BR112017024719A2 BR112017024719A BR112017024719A BR112017024719A2 BR 112017024719 A2 BR112017024719 A2 BR 112017024719A2 BR 112017024719 A BR112017024719 A BR 112017024719A BR 112017024719 A BR112017024719 A BR 112017024719A BR 112017024719 A2 BR112017024719 A2 BR 112017024719A2
- Authority
- BR
- Brazil
- Prior art keywords
- purine
- hydroxyl compounds
- compounds
- hydroxyl
- tnfa
- Prior art date
Links
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 title abstract 2
- 101100135858 Caenorhabditis elegans pde-2 gene Proteins 0.000 abstract 1
- 101150033527 TNF gene Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/10—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
é divulgada uma série de compostos de hidroxil purina e o seu uso como inibidores de pde2 e tnfa, em particular os compostos como mostrados na fórmula (i), (i) ou seus tautômeros ou sais farmaceuticamente aceitáveis.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510259502.0 | 2015-05-20 | ||
CN201510259502 | 2015-05-20 | ||
PCT/CN2016/081102 WO2016184312A1 (zh) | 2015-05-20 | 2016-05-05 | 羟基嘌呤类化合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112017024719A2 true BR112017024719A2 (pt) | 2018-11-06 |
BR112017024719B1 BR112017024719B1 (pt) | 2023-12-05 |
Family
ID=57319469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017024719-4A BR112017024719B1 (pt) | 2015-05-20 | 2016-05-05 | Compostos de hidroxil purina e seu uso |
Country Status (7)
Country | Link |
---|---|
US (1) | US10278973B2 (pt) |
EP (1) | EP3299371B1 (pt) |
JP (1) | JP6511692B2 (pt) |
CN (1) | CN107709323B (pt) |
BR (1) | BR112017024719B1 (pt) |
RU (1) | RU2685417C1 (pt) |
WO (1) | WO2016184312A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107614501B (zh) * | 2015-05-20 | 2020-01-14 | 广东众生睿创生物科技有限公司 | 羟基嘌呤类化合物及其应用 |
EP3572401B1 (en) * | 2017-01-22 | 2021-09-29 | Fujian Cosunter Pharmaceutical Co., Ltd. | Ask1 inhibitor and preparation method and use thereof |
JP2019014656A (ja) * | 2017-07-03 | 2019-01-31 | 宇部興産株式会社 | プリン誘導体化合物及びプリン誘導体化合物変性共役ジエン重合体 |
CA3090445A1 (en) * | 2018-03-15 | 2019-09-19 | Axxam S.P.A. | Substituted pyrazoles ffa4/gpr120 receptor agonists |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5069708A (en) * | 1989-07-14 | 1991-12-03 | Basf Aktiengesellschaft | Pyrimido(5,4-e)-as-triazine-5,7(6H,8H)-diones |
ATE303994T1 (de) * | 1994-12-29 | 2005-09-15 | Univ California | Verbindungen für ceramid-vermittelter signalübertragung |
US6323201B1 (en) * | 1994-12-29 | 2001-11-27 | The Regents Of The University Of California | Compounds for inhibition of ceramide-mediated signal transduction |
PA8539301A1 (es) * | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Inhibidores de la metaloproteinasa de la matriz |
KR100926247B1 (ko) * | 2001-02-24 | 2009-11-12 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 크산틴 유도체를 포함하는 약제학적 조성물 및 이의제조방법 |
CA2495432A1 (en) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
DE10235225B3 (de) * | 2002-08-01 | 2004-01-22 | Albert-Ludwigs-Universität Freiburg | Verfahren zur Durchführung chemischer Reaktionen unter Beteiligung von an fluorierten Trägermaterialien über Fluor-Fluor-Wechselwirkungen adsorbierten Verbindungen, fluoriertes Trägermaterial sowie die Verwendung des Trägermaterials |
WO2006136822A1 (en) | 2005-06-21 | 2006-12-28 | University Court Of The University Of Dundee | Inhibitor compounds |
US20110053961A1 (en) * | 2009-02-27 | 2011-03-03 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
TW201623257A (zh) * | 2014-05-09 | 2016-07-01 | 奧利安公司 | 藥理活性之喹唑啉二酮衍生物 |
PL3193880T3 (pl) * | 2014-09-19 | 2020-09-07 | Eli Lilly And Company | Hamowanie kanału jonowego receptora przejściowego potencjału A1 |
USRE49128E1 (en) | 2014-10-09 | 2022-07-12 | Guangdong Raynovent Biotech Co., Ltd. | Hydroxyl purine compounds and applications thereof |
-
2016
- 2016-05-05 US US15/575,037 patent/US10278973B2/en active Active
- 2016-05-05 EP EP16795799.2A patent/EP3299371B1/en active Active
- 2016-05-05 JP JP2017560555A patent/JP6511692B2/ja active Active
- 2016-05-05 CN CN201680029176.7A patent/CN107709323B/zh active Active
- 2016-05-05 BR BR112017024719-4A patent/BR112017024719B1/pt active IP Right Grant
- 2016-05-05 WO PCT/CN2016/081102 patent/WO2016184312A1/zh active Application Filing
- 2016-05-05 RU RU2017144120A patent/RU2685417C1/ru active
Also Published As
Publication number | Publication date |
---|---|
JP2018515559A (ja) | 2018-06-14 |
BR112017024719B1 (pt) | 2023-12-05 |
JP6511692B2 (ja) | 2019-05-15 |
CN107709323A (zh) | 2018-02-16 |
EP3299371A1 (en) | 2018-03-28 |
CN107709323B (zh) | 2020-11-20 |
WO2016184312A1 (zh) | 2016-11-24 |
RU2685417C1 (ru) | 2019-04-18 |
US20180140607A1 (en) | 2018-05-24 |
EP3299371A4 (en) | 2018-06-20 |
EP3299371B1 (en) | 2021-08-25 |
US10278973B2 (en) | 2019-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019000941A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret. | |
CL2015003686A1 (es) | Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades | |
CY1122098T1 (el) | Παραγωγα ισοχρωμενιου ως αναστολεις κινασων φωσφοϊνοσιτιδης-3 | |
UA111804C2 (uk) | ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК ІНГІБІТОРИ ЯНУС-ЗАЛЕЖНИХ КІНАЗ (JAK) | |
CL2013002063A1 (es) | Compuestos derivados de pirrolo(piridina, pirimidina o pirazina), inhibidores de serina/trionina cinasa; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer, infecciones inflamaciones y enfermedades autoinmune. | |
NI201500048A (es) | Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih | |
BR112016024538A2 (pt) | sais de adição de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-di-hidro¬pirrolo[1,2-f][1,2,4]triazina-5-carbonitrila | |
CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
BR112017001058A2 (pt) | inibidores derivados de 2-h-indazole como quinase ciclina dependente (cdk) e seus usos terapêuticos | |
BR112016028288A2 (pt) | ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto? | |
CR20160400A (es) | Derivados de nucleosido sustituidos con 4´-difluorometilo como inhibidores de la replicación de arn de la influenza | |
BR112017008659A2 (pt) | ?métodos e compostos de agonista de gip? | |
BR112015022993A8 (pt) | inibidores de jak2 e alk2 e métodos para sua utilização. | |
PH12017500732A1 (en) | Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine | |
BR112016015057A2 (pt) | Compostos e composições farmacêuticas e respectivos usos | |
BR112017025781A2 (pt) | derivados de 2-(pirazolopiridin-3-il)pirimidina como inibidores de jak | |
EA201890820A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ДВОЙСТВЕННЫХ ИНГИБИТОРОВ DYRK1/CLK1 | |
UY36265A (es) | “derivados de pirrolo[2,3-d]pirimidina”. | |
CL2019001694A1 (es) | Compuestos de pirazolopirimidina y métodos de uso de los mismos. | |
NI201700129A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa. | |
BR112017023038A2 (pt) | imidazopirazinas e pirazolopirimidinas e seu uso como moduladores do receptor ampa | |
BR112017024719A2 (pt) | compostos de hidroxil purina e seu uso | |
BR112017009012A2 (pt) | derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso | |
NI201500175A (es) | Compuestos nuevos para el tratamiento del cáncer | |
NZ731344A (en) | Hydroxyl purine compounds and applications thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: GUANGDONG RAYNOVENT BIOTECH CO., LTD. (CN) |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/05/2016, OBSERVADAS AS CONDICOES LEGAIS |